# The important role of comorbidities in the management of obesity

**Authors:** Sarah R Barenbaum, Beverly G Tchang, Louis J Aronne

PMC · DOI: 10.1210/jendso/bvag012 · Journal of the Endocrine Society · 2026-01-20

## TL;DR

This paper discusses how obesity is linked to many health issues and social problems, and highlights the need for comprehensive treatment and long-term care.

## Contribution

The paper emphasizes the importance of managing obesity's comorbidities through coordinated, multidisciplinary care.

## Key findings

- Obesity is associated with over 200 complications affecting multiple organ systems.
- Effective obesity management requires long-term follow-up and individualized treatment strategies.
- Treating obesity and its comorbidities can improve health outcomes and reduce healthcare costs.

## Abstract

Obesity is a chronic, multifactorial disease associated with more than 200 complications including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, dyslipidemia, hypertension, premature mortality, and numerous other adverse effects spanning multiple organ systems. In addition to these health complications, obesity also contributes to weight stigma and bias, which negatively affect access to care, treatment outcomes, and quality of life. Together, these complications and social consequences drive high morbidity, premature mortality, and increasing healthcare costs. Early diagnosis of obesity and systematic screening for related conditions are essential to improving health outcomes. Clinicians must treat obesity in addition to managing its complications, offering individualized strategies that may include lifestyle modification, pharmacotherapy, and bariatric surgery. Because obesity is a chronic and relapsing disease, effective management requires long-term follow-up and coordinated care through a multidisciplinary team. The effective treatment of obesity and its comorbidities can improve individual health outcomes, reduce healthcare costs, and reduce the global burden of chronic disease.

## Linked entities

- **Diseases:** type 2 diabetes (MONDO:0005148), cardiovascular disease (MONDO:0004995), obstructive sleep apnea (MONDO:0007147), dyslipidemia (MONDO:0002525)

## Full-text entities

- **Genes:** LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}
- **Diseases:** coronary artery disease (MESH:D003324), overweight (MESH:D050177), stress urinary incontinence (MESH:D014550), fatigue (MESH:D005221), depression (MESH:D003866), Class III obesity (MESH:D009765), adiposity (MESH:D018205), gestational diabetes (MESH:D016640), Weight regain (MESH:D055191), arrythmias (MESH:D001145), organ dysfunction (MESH:D009102), heart failure (MESH:D006333), mood disorders (MESH:D019964), weight gain (MESH:D015430), cardiometabolic or musculoskeletal complications (MESH:D009140), type 2 diabetes (MESH:D003924), obstructive sleep apena (MESH:D020181), metabolic dysfunction-associated steatohepatitis (MESH:D005234), visceral adiposity (MESH:D007418), obstructive sleep apnea/obesity hypoventilation syndrome (MESH:D010845), chronic diseases (MESH:D002908), systemic and pulmonary hypertension (MESH:D006976), pulmonary embolism (MESH:D011655), osteoarthritis (MESH:D010003), metabolic disease (MESH:D008659), atherosclerosis (MESH:D050197), gout (MESH:D006073), dyslipidemia (MESH:D050171), pain (MESH:D010146), hypertension (MESH:D006973), PCOS (MESH:D011085), Barrett's esophagus (MESH:D001471), cardiometabolic disease (MESH:D024821), hyperlipidemia (MESH:D006949), cirrhosis (MESH:D005355), hyperandrogenism (MESH:D017588), inflammation (MESH:D007249), MASLD (MESH:D008107), GERD (MESH:D005764), Excess (MESH:D006970), disease (MESH:D004194), insulin resistance (MESH:D007333), anxiety (MESH:D001007), asthma (MESH:D001249), chronic kidney disease (MESH:D051436), OSA (MESH:C535586), Weight stigma (MESH:D015431), deep vein thrombosis (MESH:D020246), esophageal adenocarcinoma (MESH:D000230), atrial fibrillation (MESH:D001281), endothelial dysfunction (MESH:D014652), end stage kidney failure (MESH:D007676), diabetes (MESH:D003920), cardiovascular disease (MESH:D002318), fibromyalgia (MESH:D005356), CKD (MESH:D012080), biliary calculus (MESH:D002137), psychiatric (MESH:D001523)
- **Chemicals:** lipid (MESH:D008055), free fatty acids (MESH:D005230), glucose (MESH:D005947), aldosterone (MESH:D000450), triglycerides (MESH:D014280)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12927885/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12927885/full.md

## References

82 references — full list in the complete paper: https://tomesphere.com/paper/PMC12927885/full.md

---
Source: https://tomesphere.com/paper/PMC12927885